Stock Screener App

Frei -

Installieren

Drug Manufacturers - Major

77.94

3.45% 2.60

after-market

Handel nachbörslich: 76.85 -1.09 -1.40%

Astrazeneca PLC (AZN)

Überblick Nachrichten Preisverlauf Optionskette Warum fällt AZN? Forum Prognose Aktiensplit Dividendenhistorie

Astrazeneca PLC Aktie (AZN) Neueste Nachrichten

AstraZeneca’s Promising Phase 2b Study on AZD2373 for Kidney Disease - TipRanks

AstraZeneca’s CAPItello-292 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks

AstraZeneca’s Real-World Study on Acalabrutinib in CLL Patients: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Phase I Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Phase III Study on AZD0901 for Gastric Cancer - TipRanks

AstraZeneca’s Olaparib Study Completion: Implications for Investors - TipRanks

AstraZeneca's Young Health Programme Earns Top Industry Honor for Healthcare Leadership - Stock Titan

AstraZeneca, Stockholders Far Apart In Merger Damages Tally - Law360

AstraZeneca’s Phase 3 Study on Anifrolumab: A Potential Breakthrough for Lupus Treatment - TipRanks

AstraZeneca’s Phase III Study on Dato-DXd in Advanced Breast Cancer: Key Insights for Investors - TipRanks

AstraZeneca’s CRT Study in Russia: Implications for Lung Cancer Treatment - TipRanks

AstraZeneca’s iCaReMe Global Registry: A Game Changer in Real-World Data Collection - TipRanks

AstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - TipRanks

AstraZeneca’s Real-World Study on NSCLC Drugs: Key Insights for Investors - The Globe and Mail

AstraZeneca’s Real-World Study on Tezepelumab: Implications for Severe Asthma Treatment - TipRanks

AstraZeneca’s New CKD Study: A Strategic Move in the Chinese Market - TipRanks

AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer in Cardiovascular Health - TipRanks

AstraZeneca Sees Slight Change in Voting Rights by Capital Group - TipRanks

Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail

Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana - sg.finance.yahoo.com

Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - Benzinga

AstraZeneca’s PROGRESS-CKD Study: A New Frontier in Hypertension and Kidney Disease Research - TipRanks

AstraZeneca’s DESTINY-Lung03: A Promising Phase Ib Study in NSCLC - TipRanks

AstraZeneca’s Phase II Study on AZD9291: A Promising Update for NSCLC Treatment - TipRanks

AstraZeneca’s AZD9291 Trial: A New Hope for Lung Cancer Treatment? - TipRanks

AstraZeneca: Great Portfolio, But Not A Great Price (NASDAQ:AZN) - Seeking Alpha

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

AstraZeneca’s CARDIO-TTRansform Study: A Potential Game-Changer for ATTR CM Treatment - The Globe and Mail

AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment - The Globe and Mail

AstraZeneca’s Andexanet Alfa Study: Real-World Insights for Investors - The Globe and Mail

AstraZeneca’s Real-World Study on Koselugo: Key Insights for Investors - The Globe and Mail

AstraZeneca’s Phase II Study on Olaparib in Ovarian Cancer: A Market Perspective - The Globe and Mail

AstraZeneca’s Anifrolumab Study: A Potential Game-Changer in Inflammatory Myopathies - TipRanks

AstraZeneca’s Promising Phase 2b Study on AZD2693 for NASH: Key Insights for Investors - TipRanks

AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment - TipRanks

AstraZeneca’s Latest NSCLC Study: A Potential Game-Changer? - The Globe and Mail

AstraZeneca’s AZD6234 Study: A Potential Game-Changer for Renal Impairment Treatment - TipRanks

AstraZeneca’s Phase I Study on AZD4954: A Potential Game-Changer in Cardiovascular Treatment - The Globe and Mail

AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks

AstraZeneca’s ARTEMIDE-Lung03 Study: A New Frontier in NSCLC Treatment - TipRanks

AstraZeneca’s PANGEIA-2 Study: Unveiling New Insights in Breast Cancer Mutations - TipRanks

AstraZeneca’s TROPION-Lung05 Study: A New Hope for Advanced NSCLC - TipRanks

AstraZeneca’s New Trial: Exploring AZD8421 for Advanced Cancers - TipRanks

AstraZeneca’s Real-World Study on mCRPC Treatment: Key Insights for Investors - TipRanks

AstraZeneca’s New Study on TDC Treatment for mNSCLC: Key Insights for Investors - TipRanks

Inside AstraZeneca’s long-term strategy in lung cancer - BioPharma Dive

Swedish Shares in North America – AstraZeneca Rises 1.1 Percent - MarketScreener

AstraZeneca’s Promising Phase II Study on AZD6234: A Potential Game-Changer for Type 2 Diabetes - TipRanks

AstraZeneca’s New COPD Study: Potential Market Shifts Ahead - TipRanks

Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma - TipRanks

AstraZeneca’s Promising Study on Durvalumab for Advanced Biliary Tract Cancers - TipRanks

AstraZeneca’s New Study on AZD5004: Potential Market Implications - TipRanks

AstraZeneca’s Phase III Study on Advanced Liver Cancer: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Study on Volrustomig for Mesothelioma: Key Insights for Investors - TipRanks

AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies? - TipRanks

AstraZeneca’s New Phase III Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

AstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast Cancer - TipRanks

AstraZeneca’s MaesTTRo Study: Real-world Insights into ATTR Amyloidosis - TipRanks

AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks

AstraZeneca’s Study on ATTR PN in Russian CTS Patients: Key Insights for Investors - TipRanks

AstraZeneca’s COPD Study: Key Insights and Market Impact - TipRanks

AstraZeneca’s HK-QIP Study: A Step Forward in Hyperkalemia Management - TipRanks

AstraZeneca’s New Study on NSCLC Treatment Patterns: What Investors Need to Know - TipRanks

AstraZeneca’s Innovative Phase 1 Study Targets KRAS Mutations in Advanced Tumors - TipRanks

AstraZeneca’s New Study Aims to Revolutionize COPD Care - TipRanks

AstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - The Globe and Mail

AstraZeneca’s New Study on AZD6234: Implications for Renal Impairment Treatment - The Globe and Mail

AstraZeneca’s Myasthenia Gravis Study in China: Key Insights for Investors - TipRanks

AstraZeneca Advances NASH Research with New Clinical Study - TipRanks

September 26th Options Now Available For AstraZeneca (AZN) - Nasdaq

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters